Evidence map›Paper›PMID 40872501›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Qifu Decoction Alleviates Lipopolysaccharide-Induced Myocardial Dysfunction by Inhibiting TLR4/NF-κB/NLRP3 Inflammatory Pathway and Activating PPARα/CPT Pathway.

Lingxin Zhuo, Mingxuan Ma, Jiayi Zhang, Jiayu Zhou, Yuqi Zheng, Aiyin Liang, Qingqing Sun, Jia Liu, Wenting Liao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lingxin ZhuoDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Mingxuan MaDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Jiayi ZhangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Jiayu ZhouDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Yuqi ZhengDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Aiyin LiangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Qingqing SunDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Jia LiuPharmic Laboratory Animal Center, China Pharmaceutical University, Nanjing 210009, China.
Wenting LiaoDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0001-8048-038X

Funding

National Innovation and Entrepreneurship Training Program for Undergraduate No. 202410316052YPostgraduate Research & Practice Innovation Program of Jiangsu Province Nos. KYCX24_1023, SJCX25_0292Science and Technology Planning Project of Jiangsu Provincial Administration of Traditional Chinese Medicine No. MS2023174
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

fatty acid oxidationPPARα/CPT pathwayQifu decoctionsepsis-induced cardiomyopathyTLR4/NF-κB/NLRP3 inflammatory pathway

Identifiers

PMID40872501
PMCPMC12389671

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.